NEBRETTA BLOUNT: Open Payments
NPI 1720316854 · NEWPORT NEWS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$420 in 13 payments from 12 companies in 2025. Trend: 2023 $212 · 2024 $278 · 2025 $420
Food & beverage: $420
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 1 | $111 |
| Dexcom, Inc. | 1 | $75 |
| Lilly USA, LLC | 2 | $37 |
| BETA BIONICS, INC. | 1 | $30 |
| Corcept Therapeutics | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Mannkind Corporation | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Abbott Laboratories | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
Products named: Omnipod, Dexcom G6 Transmitter, MOUNJARO, iLet Bionic Pancreas, Korlym, INSPIRE, AFREZZA, GVOKE HYPOPEN.
Industry payments across VA — which companies pay providers there.
